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Abstract 
Introduction. The incidence of skin cancer in heart transplant (HT) patients is higher than in the general population, 
reversing the proportion of cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) with a 
predominance of the former. The etiologic role of new immunosuppressants is not well known. We sought to 
ascertain the incidence of SCC and BCC in HT patients and the risk factors for its occurrence. 
Patients and Methods. We report the incidence of all types of post-HT skin cancer, SCC, and BCC among adult HT 
patients in Spain (4089 subjects) as well as the influence of gender, age at heart transplant, immunosuppression, and 
sunlight exposure. 
Results. The incidence rates of SCC and BCC, per 1000 persons/year, were 8.5 and 5.2, respectively. Males had a 
higher risk of SCC but not BCC. Induction therapy increased the risk of SCC and BCC. The relative risk of 
mycophenolate mofetil (MMF) was 0.3 (0.2–0.6; P < .0005) and azathioprine (AZA) 1.8 (1.2–2.7; P < .0032) for 
SCC, whereas tacrolimus and cyclosporine showed no difference. The relative risk of BCC was not affected by any 
immunosuppressant. 
Conclusion. Age at transplantation >45 years, induction therapy use, and high sunshine zone were risk factors for 
both SCC and BCC. Different immunosuppressive agents have different risks of nonmelanoma skin cancer, as AZA 
increases the risk of SCC and MMF is a protective factor. The relative risk of BCC was not affected by any 
immunosuppressor. 
Skin cancers are the most common malignancies among solid organ transplant recipients.1 Epidemiologic 
data have shown that skin cancer is more frequent in sun-exposed areas and in light-skinned individuals 
with blue eyes and blonde hair.2 Age, immunosuppressive therapy, and viral warts could also be 
important risk factors.3, 4 and 5 Most of the data about the incidence of skin cancer in transplant patients is 
from kidney recipients,6, 7, 8 and 9 but there are not as many studies in heart transplant (HT) patients, who 
generally receive higher levels of immunosuppressive therapy than do other transplant recipients. 
Regarding the type of skin cancer, it has been reported that cutaneous squamous cell carcinoma (SCC) 
is more frequent than basal cell carcinoma (BCC) in transplant patients, as opposed to the situation in the 
general population,3, 5, 6, 10, 11 and 12 although not all studies obtain the same results,7 and 13 suggesting that 
differences could be influenced by factors such as the length of immunosuppression,7 the sunlight 
exposure, or the quality of the registry of skin tumors.3 
Since publication of the first studies examining the influence of immunosuppression14 on the onset of 
skin cancer in heart transplantation, new drugs have appeared with widespread use, such as 
mycophenolate mofetil (MMF), tacrolimus, and interleukin (IL) 2R-blockers. To date, no study has 
examined the influence of the most commonly used immunosuppressants on the incidence of skin cancer 
BCC and SCC in patients with heart transplantation. 
The present study is based on the Spanish Post-Heart Transplant Tumor Registry (SPHTTR), 
composed of the data on tumors in all adult patients who have undergone HT in Spain from 1984 to 
December 2003. We report the incidence of all types of post-HT skin cancer, SCC, and BCC among adult 
HT patients in Spain, as well as the influence of gender, age at heart transplantation, immunosuppression, 
antiviral prophylaxis, and sunlight exposure. 
  
Methods 
Patients and Study Protocol 
A total of 4089 patients aged >15 years who underwent HT in Spain between 1984 and December 31, 
2003, were identified in the SPHTTR. We excluded patients who died in the first 3 months after HT (n = 
695) and 1 patient for whom the date of diagnosis of a first post-HT tumor had not been recorded. The 
remaining 3393 patients were followed to December 2004. 
Variables 
The outcome data analyzed were the occurrence of post-HT skin cancers (SCC and BCC), together with 
date of diagnosis and location. The treatment variables considered were the use of induction therapy, the 
agents employed for this purpose, and the duration of treatment; the agents used for maintenance of 
immunosuppression in each of 4 post-HT periods (the first 3 months, months 4–12, months 13–24, and 
>2 years post-HT). Other possible risk factors considered were gender, pre-HT smoking, and age at HT 
(<45, 45–54, 55–64, and ≥65 years). 
Sunlight exposure was evaluated according to data from the Spanish National Institute of Meteorology 
from 1997 to 2004. Hospitals that performed HT (n = 16) were divided into 2 groups: Zone 1 (4 hospitals) 
of low sunshine (<2500 hours of sunshine per year) and zone 2 (12 hospitals) of high sunshine (>2500 
hours of sunshine per year). 
Statistical Analysis 
For each patient, the number of years at risk was defined as the time between the date of HT and 
December 2004 or death, whichever occurred first. The incidence, per 1000 person-years, of skin cancer, 
and of both SCC and BCC, was estimated for each gender and age group, and for follow-up to 3 months, 
6 months, and 1, 2, 3, 4, 5, and 10 years. Univariate risk analyses were performed to estimate the 
influence of age group, gender, pre-HT smoking, MMF in the first 3 months, tacrolimus in the first 3 
months, induction therapy, induction with OKT3, induction with either equine or rabbit anti-thymocyte 
globulin (ATG), induction with basiliximab, induction with daclizumab, and hours of sunshine per year. 
Multivariate Poisson regression models were fitted in which the association of tumors with induction 
in general and with induction by OKT3 and by ATG was evaluated while adjusting for age group, gender, 
pre-HT smoking, and immunosuppression in the first 3 months with MMF and/or tacrolimus. The 
criterion for statistical significance was P < .05. 
Results 
As described,14 in the SPHTTR 3393 patients were followed to December 2004. Most (84.7%) of the 
patients were men, and the age at the time of transplantation was 51.4 ± 11.0 years, with a median follow-
up of 5.2 years (mean, 5.8; maximum, 20.2). By age group, 762 patients (22.5%) were aged <45 years, 
1044 (30.8%) 45–54 years, 1365 (40.2%) 55–64 years, and 222 (6.5%) >65 years. Of the patients, 48.9% 
had been smokers before HT. Data on the use of individual immunosuppressive agents are listed in Table 
1. Steroids were used by virtually all patients in the first 3 months post-HT, and by 62.2% after 2 years. 
The use of cyclosporine and azathioprine declined gradually with increasing time post-HT, whereas 
tacrolimus, MMF, and sirolimus exhibited the reverse trend. OKT3, ATG, basiliximab, and daclizumab 
were used almost exclusively in the first 3 months post-HT, presumably for induction therapy. On this 
basis, induction therapy was used in 60.5% of the patients. 
 
  
Table 1. Patients Receiving Each Kind of Immunosuppresor (Percentages) by Period Post-HT 
 <3 Months 3–12 Months* 1–2 Years† >2 Years† At Any Time 
      
n 3393 3127 2763 2763 — 
Cyclosporine 79.1 73.6 73.0 64.4 84.4 
Azathioprine 60.5 53.7 54.1 42.7 68.8 
Prednisone 98.5 83.2 73.7 62.2 99.2 
Tacrolimus 8.3 12.2 12.6 17.2 21.9 
MMF 25.6 28.4 27.5 40.2 48.0 
Sirolimus 0.4 0.5 0.5 6.3 6.6 
Everolimus 0.2 0.2 0.2 0.6 0.8 
OKT3 37.4 0.2 0.0 0.2 44.3 
ATG 14.3 1.7 0.4 0.3 17.1 
Basiliximab 5.6 0.0 0.0 0.0 6.7 
Daclizumab 3.4 0.0 0.0 0.0 4.1 
      
 
* Percentages of the 3127 patients who survived 1 year. 
† Percentages of the 2763 patients who survived 2 years. 
A total of 324 skin cancers developed in 204 patients with the following distribution: 169 (54.2%) 
were SCC, 104 BCC (33.3%), 9 melanoma, 39 miscellaneous (4 Kaposi sarcoma, 23 undifferentiated 
malignant tumors, 5 adenocarcinoma, 6 metastatic, 1 neuroectodermal), and 3 unknown. 
For the analysis of the incidence, per 1000 person-years, we excluded 12 tumors (9 melanoma and 3 
unknown) and we achieved a follow-up of 19,883.4 person-years. Skin cancer (nonmelanoma) had an 
incidence of 15.7 cases per 1000 person-years (95% confidence interval [CI], 14–17.5), SCC had an 
incidence of 8.5 cases per 1000 person-years (95% CI, 7.3–9.9), and BCC 5.2 cases per 1000 person-
years (95% CI, 4.3–6.3). The incidence of skin cancer (nonmelanoma), SCC, and BCC at 3 and 6 months, 
and 1, 2, 3, 4, 5, and 10 years is shown in Table 2. The incidence of nonmelanoma skin cancer was 16.6 
(95% CI, 14.8–18.7) in men and 10.5 (95% CI, 7.4–15) in women. Both SCC and BCC were more 
common in men than women. In men, the incidence of SCC was higher than BCC, 9.3 (95% CI, 7.9–
10.8) versus 5.4 (95% CI, 4.4–6.6); in women, the incidence of SCC and BCC was similar, 4.1 (95% CI, 
2.3–7.2) versus 4.4 (95% CI, 2.6–7.6). The relative risk for men was 1.6 (1.1–2.3; P = .0155) for 
nonmelanoma skin cancer, 2.3 (1.3–4.1; P = .0048) for SCC, and 1.2 (0.7–2.2; P = .5083) for BCC. 
Table 2. Incidence of Nonmelanoma Skin Cancer, SCC, and BCC 
  Skin cancer (Nonmelanoma)  Skin Cancer (SCC)  Skin Cancer (BCC) 
 Person-years Tumors IR* (95% CI†)  Tumors IR* (95% CI†)  Tumors 
         
Overall 19,883.4 312 15.7 (14–17.5)  169 8.5 (7.3–9.9)  104 
Cumulative at         
3 months 846.3 2 2.4 (0.6–9.5)  0 —  1 
6 months 1.674.4 6 3.6 (1.6–8)  1 0.6 (0.1–4.2)  4 
1 year 3.260.8 16 4.9 (3–8)  3 0.9 (0.3–2.9)  10 
2 years 6.159.9 38 6.2 (4.5–8.5)  17 2.8 (1.7–4.4)  15 
3 years 8.678.1 56 6.5 (5–8.4)  25 2.9 (2–4.3)  21 
4 years 10.886.6 78 7.2 (5.7–9)  39 3.6 (2.6–4.9)  26 
5 years 12.787.3 109 8.5 (7.1–10.3)  53 4.1 (3.2–5.4)  38 
10 years 18.306.4 260 14.2 (12.6–16)  142 7.8 (6.6–9.1)  85 
Gender         
Male 16.940.0 281 16.6 (14.8–18.7)  157 9.3 (7.9–10.8)  91 
Female 2.943.4 31 10.5 (7.4–15)  12 4.1 (2.3–7.2)  13 
Age group (y)         
<45 5.259.0 23 4.4 (2.9–6.6)  11 2.1 (1.2–3.8)  10 
45–54 6.135.1 86 14 (11.4–17.3)  51 8.3 (6.3–10.9)  23 
55–64 7.547.1 179 23.7 (20.5–27.5)  98 13 (10.7–15.8)  64 
≥65 942.2 24 25.5 (17.1–38)  9 9.6 (5–18.4)  7 
         
 
* Incidence per 1000 person-years. 
† Confidence interval. 
  
For nonmelanoma skin cancer, the incidence per 1000 person-years increased from 4.4 among patients 
aged <45 years at HT to 25.5 among patients aged ≥65 years (Table 2), with relative risks of 3.2 (95% CI, 
2–5.1; P < .0001) for 45–54 year-olds, 5.4 (3.5–8.4; P < .0001) for 55–64 year-olds, and 5.8 (3.3–10.3; P 
< .0001) among patients aged ≥65 years, relative to those under 45 ( Table 3). Similarly, for SCC, the 
incidence increased from 2.1 in the youngest age group to 9.6 in the oldest, with relative risks of 4 (95% 
CI, 2.1–7.6; P < .0001), 6.2 (3.3–11.6; P < .0001), and 4.6 (1.9–11; P < .0002) relative to those under 45. 
Likewise, for BCC, the incidence increased from 1.9 in the youngest age group to 7.4 in the oldest 
(relative risk [RR], 3.9; 95% CI, 1.5–10.3; P < .002) relative to those under 45. 
Table 3. RR of Nonmelanoma Skin Cancer, SCC, and BCC Associated With Various Factors 
 Skin Cancer (Nonmelanoma) 
 
Skin Cancer (SCC) 
 
Skin Cancer (BCC) 
 RR (95% CI) P Value 
 
RR (95% CI) P Value 
 
RR (95% CI) 
        
Gender        
Male 1.6 (1.1–2.3) .0155  2.3 (1.3–4.1) .0048  1.2 (0.7–2.2) 
Female 1.00 —  1.00 —  1.00 
Age group (y)        
<45 1.00 —  1.00 —  1.00 
45–54 3.2 (2–5.1) <.0001  4 (2.1–7.6) <.0001  2 (0.9–4.1) 
55–64 5.4 (3.5–8.4) <.0001  6.2 (3.3–11.6) <.0001  4.5 (2.3–8.7) 
≥65 5.8 (3.3–10.3) <.0001  4.6 (1.9–11) .0002  3.9 (1.5–10.3) 
Pre-HT smoking 1.1 (0.9–1.3) .5155  1.3 (1–1.7) .0941  0.9 (0.6–1.3) 
        
 
CI, confidence interval; RR, relative risk. 
 
When we analyzed the influence of the use of different immunosuppressive drugs in the first 3 months 
after HT and regardless of any later use, MMF and tacrolimus were both associated with a lower risk of 
nonmelanoma skin cancer, at the expense of a reduction in the risk of SCC (RR, 0.3; 95% CI, 0.2–0.6; P 
= .0005 for MMF and RR, 0.00; P = .007 for tacrolimus) but not in the BCC incidence (RR, 0.7; 95% CI, 
0.4–1.3; P = .21 for MMF and RR, 0.7; 95% CI, 0.2–2.2; P = .55 for tacrolimus). Azathioprine was 
associated with an increased SCC risk (RR, 1.8; 95% CI, 1.2–2.7; P = .003) and cyclosporine was neutral. 
Induction therapy was a risk factor for nonmelanoma skin cancer (RR, 2.1; 95% CI, 1.6–2.7; P < 
.0001), SCC (RR, 2.3; 95% CI, 1.6–3.4; P < .0001) and BCC (RR, 2.6; 95% CI, 1.6–4.2; P < .0001), but 
only OKT3 was associated with both SCC and BCC ( Table 4). In the univariate analyses, the influence 
of ATG differed from that of OKT3 in that ATG was associated only with an increased risk of BCC (RR, 
2.2; 95% CI, 1.2–4; P = .0102). 
  
Table 4. RR of Nonmelanoma Skin Cancer, SCC, and BCC Associated With Various Factors 
 Skin cancer (Nonmelanoma)  Skin Cancer (SCC)  Skin Cancer (BCC) 
 RR (95% CI) P Value  RR (95% CI) P Value  RR (95% CI) P Value 
         
MMF (yes/no) 0.5 (0.3–0.7) .0002  0.3 (0.2–0.6) .0005  0.7 (0.4–1.3) .2123 
Tacrolimus (yes/no) 0.2 (0.1–0.7) .0058  0.00 .0077  0.7 (0.2–2.2) .5524 
Azathioprine (yes/no) 1.5 (1.1–1.9) .0074  1.8 (1.2–2.7) .0032  1.5 (0.9–2.4) .1052 
Cyclosporine (yes/no) 1.1 (0.8–1.5) .6810  1.4 (0.9–2.3) .1456  1.1 (0.6–1.9) .7415 
Induction therapy 2.1 (1.6–2.7) <.0001  2.3 (1.6–3.4) <.0001  2.6 (1.6–4.2) .0001 
OKT3 2.5 (1.9–3.3) <.0001  3 (2.1–4.3) <.0001  2.9 (1.8–4.8) <.0001 
ATG/thymoglobulin 1.6 (1.1–2.2) .0156  1.2 (0.7–2.1) .4354  2.2 (1.2–4) .0102 
Basiliximab 0.5 (0.1–2.1) .3401  0.00 .1619  0.9 (0.1–6.7) .9186 
Daclizumab 0.00 .1496  0.00 .3083  0.00 .4428 
  Sunlight exposure (h/y) 
<2500 1.00 —  1.00 —  1.00 — 
>2500 5.7 (3.7–8.8) <.0001  8.7 (4.3–17.8) <.0001  3 (1.7–5.4) .0001 
         
 
ATG, antithymocyteglobulin; CI, confidence interval; RR, relative risk. 
 
The relative risk of developing SCC in patients who were transplanted in a high sunshine zone (>2500 
hours/year) was 8.7 (95% CI, 4.3–17.8; P < .0001) in relation to patients who were transplanted in a low 
sunshine zone, and in BCC the RR was 3 (95% CI, 1.7–5.4; P = .0001). 
Discussion 
Our study includes the largest number of heart transplant patients with skin tumors. As described, SCC is 
the most common skin tumor in HT recipients followed by BCC. However, the ratio between them varies 
in different studies and it has been suggested that this variability could be due to the quality of the 
registry. We found that the SCC/BCC ratio was 1.62:1, which is very similar to the ratio described by 
Caforio et al3 in a prospective study with close follow-up of HT recipients by a dermatologist. 
The incidence, per 1000 person-years, of SCC and BCC increased with time of follow-up. One 
important finding is the relationship of the gender and the type of tumor. Although both types of skin 
tumors were more common in men, in the univariate analysis this difference was significant only in SCC. 
In the univariate analysis of nonmelanoma skin cancer, the use of both MMF and FK in the first 3 
months emerged as protective factors, whereas AZA was a risk factor and cyclosporine had no effect. 
This was due to the influence of these drugs on the incidence of SCC; in BCC there was no modification, 
in agreement with the results of the study by Caforio et al, which showed that a high rejection score was a 
risk factor for skin tumor of the SCC type but not BCC.3 It is noteworthy that the group of patients 
exposed to FK showed no SCC, which suggests it is a strong protective factor, but it must be remembered 
that this was a small group of patients. The beneficial role of MMF at the onset of cancer has been 
described previously in vitro15 and 16 and in vivo,17 and 18 as has the deleterious effect of AZA,19 but there is 
little information about the effect of calcineurin inhibitors on the appearance of skin tumors in cardiac 
transplantation. 
Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes after ultraviolet B 
radiation. This suggests that the increased risk of skin cancer observed in organ transplant patients may be 
a result not only of systemic immune suppression but also the local inhibition of DNA repair and 
apoptosis in skin by calcineurin inhibitors.20 
The possible beneficial effect of FK in SCC tumors in cardiac transplantation has not been described 
previously. Referring to all types of tumors, in The International Society for Heart and Lung 
Transplantation (ISHLT) Registry the use of tacrolimus seemed to be protective in the univariate analysis, 
but it was not significant on multivariate analysis.21 Whether different immunosuppressive modalities are 
associated with an increased occurrence of nonmelanoma skin cancer in cardiac transplant recipients 
remains controversial.22 and 23 In renal transplantation, FK seems to be a risk factor for developing 
nonmelanoma skin cancer,24 and 25 but in the liver transplant population it could be protective.26 
Another surprising observation was that induction therapy resulted in an increased incidence of both 
SCC and BCC, especially among those patients who received OKT3, although ATG therapy only 
increased the incidence of BCC. According to data from the ISHLT Registry, induction 
immunosuppression does not seem to increase the risk of subsequent malignancy and neither OKT3 nor 
ATG use was associated with a significantly increased risk of malignancy.21 
Leiter et al27 reported that intensive ultraviolet light exposure in childhood and adolescence was 
causative for the development of BCC, whereas for the etiology of SCC a chronic ultraviolet light 
exposure in the earlier decades was noted. In our study, high sunlight exposure was a risk factor for the 
emergence of both types of tumors, but specially SCC, which seems to be associated with cumulative 
exposure to sunlight. 
In conclusion, the present study confirms a higher incidence of SCC versus BCC in patients with a 
heart transplant. Age >45 years, induction therapy, and high sunlight exposure are risk factors for both 
SCC and BCC. Our results suggest that the occurrence of SCC in heart transplant patients depends on the 
immunosuppressive therapy used and not just the duration and level of inmunosuppression. MMF was a 
protective factor for SCC, whereas azathioprine was a risk factor and tacrolimus and cyclosporine had no 
effect. No immunosuppressive drug was associated with BCC. 
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